Table 2.

Results of neuropsychological tests among groups sorted by treatment phase

Chemotherapy naïve (N = 5)After 1 cycle of chemotherapy (N = 20)After 3 cycles of chemotherapy (N = 20)After 7 cycles of chemotherapy (N = 19)Patients with a history of previous chemotherapy (N = 12)
pNF-H–positive, n (%)0 (0)1 (5)6 (30)11 (57.8)0 (0)
CFQa (mean, SD)21.5 ± 8.319.4 ± 11.017.5 ± 10.818.4 ± 11.425.6 ± 10.9
HADSb
 Anxiety subscale (mean, SD)5.0 ± 2.95.5 ± 2.83.7 ± 2.85.0 ± 2.94.3 ± 2.9
 Depression subscale (mean, SD)3.4 ± 4.04.7 ± 3.43.9 ± 3.44.0 ± 3.62.8 ± 3.4
STAIb
 State anxiety (mean, SD)41.6 ± 11.643.3 ± 11.138.3 ± 11.442.0 ± 11.936.9 ± 11.2
 Trait anxiety (mean, SD)45 ± 9.844.9 ± 11.435.0 ± 11.442.7 ± 11.938.1 ± 11.2
ESSb (mean, SD)6.6 ± 4.010.5 ± 4.29.2 ± 4.18.0 ± 3.88.8 ± 3.8
BFI-Jb (mean, SD)34.5 ± 17.516 ± 14.816.3 ± 14.717.3 ± 15.821.9 ± 15.7
NVSa (mean, SD)4.6 ± 0.74.2 ± 1.14.5 ± 1.14.6 ± 1.24.2 ± 1.1
JARTa (mean, SD)
 Full-scale IQ109.6 ± 7.5106.7 ± 9.4110.5 ± 9.2110.2 ± 10.0110.9 ± 9.6
 Verbal IQ111.4 ± 8.6108.1 ± 10.6112.4 ± 10.5112.1 ± 11.3112.8 ± 10.9
 Performance IQ106.3 ± 5.5104.2 ± 6.9107.0 ± 6.8106.8 ± 7.3107.2 ± 7.1
RCPMa (mean, SD)36.0 ± 1.336.0 ± 0.735.8 ± 0.735.8 ± 0.835.5 ± 0.7
PainDETECTb (mean, SD)4.1 ± 4.74.0 ± 4.83.7 ± 4.74.2 ± 5.04.2 ± 4.7
EQ5Da (mean, SD)0.8 ± 0.10.8 ± 0.10.8 ± 0.10.8 ± 0.10.8 ± 0.1

Abbreviations: CFQ, cognitive failure questionnaire; EQ5D, EuroQOL-5 Dimension questionnaire; HADS, Hospital Anxiety and Depression Scale; IQ, intelligence quotient; pNF-H, phosphorylated form of the high-molecular-weight neurofilament subunit.

  • aThe score would decrease when the function declines.

  • bThe score would increase when the function declines.